Disease Landscape and Forecast Insights

The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…

The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…